A statinok nem lipid hatásai.

Translated title of the contribution: The non-lipid effects of statins

G. Paragh, László Márk, Evelin Katona

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In the past 15 years statins have gained recognition as one of the successful drugs in cardiovascular therapy and are now regarded as important as the beta blocking agents and ACE inhibitors. Since the publication of the Scandinavian Simvastatin Survival Study in 1994, the clinical application of statins has become increasingly widespread. Numerous large-scale clinical end-point trials have demonstrated that statin therapy reduces cardiovascular morbidity and mortality. Their beneficial therapeutic effects, besides their lipid lowering role, have been attributed to their non-lipid modifying ability, called the pleiotropic effect. The clinical consequences of the latter are not well understood, simply because differentiating between their lipid modifying and pleiotropic effects is not possible in vivo. In this article the authors summarize the evidence of the pleiotropic effects based on results of the latest in vitro experiments. They describe the influence of statins on endothelial dysfunction and thrombus formation, their anti-inflammatory, plaque-stabilizing and antioxidant effects, as well as their CRP and angiogenesis modifying non-lipid effects. The authors further discuss the effects of these drugs on tumors, osteoporosis and dementia. Although all members of the statin family inhibit the same enzyme in the cholesterol synthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase), their various pharmacokinetic properties, and tissue selectivity (lipophilicity and hydrophilicity) are responsible for their different pleiotropic effects.

Original languageHungarian
Pages (from-to)1903-1910
Number of pages8
JournalOrvosi Hetilap
Volume145
Issue number37
Publication statusPublished - Sep 12 2004

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Cardiovascular Agents
Aptitude
Simvastatin
Therapeutic Uses
Hydrophobic and Hydrophilic Interactions
Angiotensin-Converting Enzyme Inhibitors
Osteoporosis
Dementia
Publications
Oxidoreductases
Thrombosis
Anti-Inflammatory Agents
Pharmacokinetics
Antioxidants
Cholesterol
Morbidity
Mortality
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paragh, G., Márk, L., & Katona, E. (2004). A statinok nem lipid hatásai. Orvosi Hetilap, 145(37), 1903-1910.

A statinok nem lipid hatásai. / Paragh, G.; Márk, László; Katona, Evelin.

In: Orvosi Hetilap, Vol. 145, No. 37, 12.09.2004, p. 1903-1910.

Research output: Contribution to journalArticle

Paragh, G, Márk, L & Katona, E 2004, 'A statinok nem lipid hatásai.', Orvosi Hetilap, vol. 145, no. 37, pp. 1903-1910.
Paragh G, Márk L, Katona E. A statinok nem lipid hatásai. Orvosi Hetilap. 2004 Sep 12;145(37):1903-1910.
Paragh, G. ; Márk, László ; Katona, Evelin. / A statinok nem lipid hatásai. In: Orvosi Hetilap. 2004 ; Vol. 145, No. 37. pp. 1903-1910.
@article{37fa9c723af94f7bbee54fd374c07a26,
title = "A statinok nem lipid hat{\'a}sai.",
abstract = "In the past 15 years statins have gained recognition as one of the successful drugs in cardiovascular therapy and are now regarded as important as the beta blocking agents and ACE inhibitors. Since the publication of the Scandinavian Simvastatin Survival Study in 1994, the clinical application of statins has become increasingly widespread. Numerous large-scale clinical end-point trials have demonstrated that statin therapy reduces cardiovascular morbidity and mortality. Their beneficial therapeutic effects, besides their lipid lowering role, have been attributed to their non-lipid modifying ability, called the pleiotropic effect. The clinical consequences of the latter are not well understood, simply because differentiating between their lipid modifying and pleiotropic effects is not possible in vivo. In this article the authors summarize the evidence of the pleiotropic effects based on results of the latest in vitro experiments. They describe the influence of statins on endothelial dysfunction and thrombus formation, their anti-inflammatory, plaque-stabilizing and antioxidant effects, as well as their CRP and angiogenesis modifying non-lipid effects. The authors further discuss the effects of these drugs on tumors, osteoporosis and dementia. Although all members of the statin family inhibit the same enzyme in the cholesterol synthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase), their various pharmacokinetic properties, and tissue selectivity (lipophilicity and hydrophilicity) are responsible for their different pleiotropic effects.",
author = "G. Paragh and L{\'a}szl{\'o} M{\'a}rk and Evelin Katona",
year = "2004",
month = "9",
day = "12",
language = "Hungarian",
volume = "145",
pages = "1903--1910",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "37",

}

TY - JOUR

T1 - A statinok nem lipid hatásai.

AU - Paragh, G.

AU - Márk, László

AU - Katona, Evelin

PY - 2004/9/12

Y1 - 2004/9/12

N2 - In the past 15 years statins have gained recognition as one of the successful drugs in cardiovascular therapy and are now regarded as important as the beta blocking agents and ACE inhibitors. Since the publication of the Scandinavian Simvastatin Survival Study in 1994, the clinical application of statins has become increasingly widespread. Numerous large-scale clinical end-point trials have demonstrated that statin therapy reduces cardiovascular morbidity and mortality. Their beneficial therapeutic effects, besides their lipid lowering role, have been attributed to their non-lipid modifying ability, called the pleiotropic effect. The clinical consequences of the latter are not well understood, simply because differentiating between their lipid modifying and pleiotropic effects is not possible in vivo. In this article the authors summarize the evidence of the pleiotropic effects based on results of the latest in vitro experiments. They describe the influence of statins on endothelial dysfunction and thrombus formation, their anti-inflammatory, plaque-stabilizing and antioxidant effects, as well as their CRP and angiogenesis modifying non-lipid effects. The authors further discuss the effects of these drugs on tumors, osteoporosis and dementia. Although all members of the statin family inhibit the same enzyme in the cholesterol synthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase), their various pharmacokinetic properties, and tissue selectivity (lipophilicity and hydrophilicity) are responsible for their different pleiotropic effects.

AB - In the past 15 years statins have gained recognition as one of the successful drugs in cardiovascular therapy and are now regarded as important as the beta blocking agents and ACE inhibitors. Since the publication of the Scandinavian Simvastatin Survival Study in 1994, the clinical application of statins has become increasingly widespread. Numerous large-scale clinical end-point trials have demonstrated that statin therapy reduces cardiovascular morbidity and mortality. Their beneficial therapeutic effects, besides their lipid lowering role, have been attributed to their non-lipid modifying ability, called the pleiotropic effect. The clinical consequences of the latter are not well understood, simply because differentiating between their lipid modifying and pleiotropic effects is not possible in vivo. In this article the authors summarize the evidence of the pleiotropic effects based on results of the latest in vitro experiments. They describe the influence of statins on endothelial dysfunction and thrombus formation, their anti-inflammatory, plaque-stabilizing and antioxidant effects, as well as their CRP and angiogenesis modifying non-lipid effects. The authors further discuss the effects of these drugs on tumors, osteoporosis and dementia. Although all members of the statin family inhibit the same enzyme in the cholesterol synthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase), their various pharmacokinetic properties, and tissue selectivity (lipophilicity and hydrophilicity) are responsible for their different pleiotropic effects.

UR - http://www.scopus.com/inward/record.url?scp=16544395457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544395457&partnerID=8YFLogxK

M3 - Article

C2 - 15493621

AN - SCOPUS:16544395457

VL - 145

SP - 1903

EP - 1910

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 37

ER -